TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #14739 · May 23

#c_lang#ctp#ctpapi#futures#options#quant#simnow#stock#tora#trader#tts#xtp openctp is a powerful open-source trading platform compatible with many Chinese securities and futures trading systems, offering both real and simulated trading environments for futures, options, stocks, funds, and bonds across domestic and global markets like A-shares, Hong Kong, and US stocks. It provides easy access to CTPAPI through Python and other programming languages, plus user-friendly trading clients with graphical and command-line interfaces. You can register free simulation accounts instantly via WeChat, enabling you to practice and test trading strategies in real-time or 24/7 environments. It also offers training, development support, and a monitoring platform for multiple trading systems, helping you learn, develop, and trade efficiently with low costs and broad market access. This benefits you by giving a flexible, comprehensive, and cost-effective way to develop, test, and execute trading strategies across many markets with strong community and technical support. https://github.com/openctp/openctp

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment